David Jakeman Sells 2,800 Shares of Chimerix, Inc. (NASDAQ:CMRX) Stock

Chimerix, Inc. (NASDAQ:CMRX) VP David Jakeman sold 2,800 shares of the business’s stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $4.10, for a total value of $11,480.00. Following the sale, the vice president now directly owns 149,287 shares of the company’s stock, valued at $612,076.70. This represents a 1.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Chimerix Trading Down 4.1 %

Chimerix stock opened at $3.94 on Monday. The firm has a market capitalization of $354.35 million, a P/E ratio of -4.19 and a beta of 0.36. The business has a 50-day moving average of $2.87 and a 200-day moving average of $1.60. Chimerix, Inc. has a 1 year low of $0.75 and a 1 year high of $4.22.

Chimerix (NASDAQ:CMRX) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.02). The company had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $1.26 million. During the same period in the prior year, the company posted ($0.27) EPS. Research analysts anticipate that Chimerix, Inc. will post -0.99 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on CMRX shares. HC Wainwright reiterated a “buy” rating and set a $11.00 price target on shares of Chimerix in a research report on Monday, December 30th. Wedbush reiterated an “outperform” rating and set a $6.00 target price on shares of Chimerix in a research report on Tuesday, December 10th.

Institutional Trading of Chimerix

A number of large investors have recently made changes to their positions in the company. Assenagon Asset Management S.A. lifted its holdings in Chimerix by 154.8% during the fourth quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company’s stock worth $2,846,000 after acquiring an additional 496,823 shares in the last quarter. Peapod Lane Capital LLC acquired a new stake in shares of Chimerix during the fourth quarter worth about $2,626,000. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Chimerix by 66.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock valued at $321,000 after purchasing an additional 138,098 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Chimerix in the 2nd quarter valued at approximately $137,000. Finally, Valeo Financial Advisors LLC increased its stake in Chimerix by 78.8% during the 4th quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company’s stock worth $509,000 after purchasing an additional 64,420 shares in the last quarter. Institutional investors own 45.42% of the company’s stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.